CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors

CSL (ASX: CSL) shares plunged sharply on Monday after the Australian biopharmaceutical giant downgraded its fiscal 2026 earnings outlook and revealed plans for major asset impairments over the next two years. The stock dropped 17.7% to A$98.59, marking its lowest level in nearly a decade and becoming the biggest drag on the ASX 200 index, which declined 1%.

The biotech company now expects net profit for the financial year ending June 2026 to reach around $3.1 billion, down from last year’s $3.3 billion. The revised forecast also falls below the company’s earlier guidance that projected profit growth between 4% and 7%. CSL additionally reduced its annual revenue forecast to $15.2 billion, compared with previous expectations for 2% to 3% growth. The downgrade surprised investors, especially after the company reaffirmed its outlook earlier this year in February.

CSL also announced it will record approximately $5 billion in non-cash impairment charges across fiscal 2026 and 2027. A large portion of the writedown is linked to its Vifor kidney treatment business, which has struggled amid changing market conditions.

According to interim CEO Gordon Naylor, the company’s turnaround strategy is progressing more slowly than expected. CSL cited difficult market conditions, geopolitical uncertainty, and potential disruptions tied to the Middle East conflict as key reasons behind the weaker outlook.

Investor sentiment toward CSL has already been under pressure throughout 2026. The company’s shares have now lost nearly 50% this year as it continues to face weak influenza vaccine demand in the critical U.S. market alongside growing competition from generic drugmakers.

The latest downgrade raises concerns about CSL’s near-term growth prospects and highlights the challenges facing the global healthcare and biotech sector in an increasingly uncertain economic environment.